JPH047227B2 - - Google Patents
Info
- Publication number
- JPH047227B2 JPH047227B2 JP59109693A JP10969384A JPH047227B2 JP H047227 B2 JPH047227 B2 JP H047227B2 JP 59109693 A JP59109693 A JP 59109693A JP 10969384 A JP10969384 A JP 10969384A JP H047227 B2 JPH047227 B2 JP H047227B2
- Authority
- JP
- Japan
- Prior art keywords
- bone
- hydroxyapatite
- composition
- powder
- filling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000988 bone and bone Anatomy 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 45
- 230000007547 defect Effects 0.000 claims description 33
- 238000011049 filling Methods 0.000 claims description 32
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 30
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 30
- 102000009123 Fibrin Human genes 0.000 claims description 25
- 108010073385 Fibrin Proteins 0.000 claims description 25
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 25
- 229950003499 fibrin Drugs 0.000 claims description 25
- 108010049003 Fibrinogen Proteins 0.000 description 27
- 102000008946 Fibrinogen Human genes 0.000 description 27
- 229940012952 fibrinogen Drugs 0.000 description 27
- 239000000843 powder Substances 0.000 description 21
- 239000008187 granular material Substances 0.000 description 15
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 14
- 108090000190 Thrombin Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 229960004072 thrombin Drugs 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 10
- 230000011164 ossification Effects 0.000 description 10
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000007979 citrate buffer Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229940078499 tricalcium phosphate Drugs 0.000 description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- 101710082399 Alpha-protein kinase 3 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 bone Chemical compound 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59109693A JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
| EP85106694A EP0166263A1 (en) | 1984-05-31 | 1985-05-30 | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59109693A JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60256460A JPS60256460A (ja) | 1985-12-18 |
| JPH047227B2 true JPH047227B2 (es) | 1992-02-10 |
Family
ID=14516800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59109693A Granted JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60256460A (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947489A4 (en) | 1996-11-25 | 2001-08-08 | Advance Kk | PROCESS FOR PRODUCING CERAMICS |
| EP2029184B1 (en) * | 2006-05-26 | 2011-02-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
| EP2021043B1 (en) | 2006-05-26 | 2011-01-12 | Baxter International Inc. | Injectable bone void filler |
| FR2932687B1 (fr) | 2008-06-23 | 2010-09-17 | Centre Nat Rech Scient | Biomateriaux a base de phosphates de calcium. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836545A (ja) * | 1981-06-25 | 1983-03-03 | セラフアルム ジ−エムビ−エイチ アンド カンパニ− ケイジイ | フイブリノ−ゲンを含有する乾燥製剤およびその製造方法 |
-
1984
- 1984-05-31 JP JP59109693A patent/JPS60256460A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836545A (ja) * | 1981-06-25 | 1983-03-03 | セラフアルム ジ−エムビ−エイチ アンド カンパニ− ケイジイ | フイブリノ−ゲンを含有する乾燥製剤およびその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60256460A (ja) | 1985-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Costantino et al. | Hydroxyapatite cement: I. Basic chemistry and histologic properties | |
| Kuemmerle et al. | Assessment of the suitability of a new brushite calcium phosphate cement for cranioplasty–an experimental study in sheep | |
| Yaylaoǧlu et al. | Development of a calcium phosphate–gelatin composite as a bone substitute and its use in drug release | |
| JP5450063B2 (ja) | 生体活性骨移植片代替物 | |
| US5047031A (en) | In situ calcium phosphate minerals method | |
| JP5792633B2 (ja) | モネタイトと他の生物活性カルシウムの複合物及びシリコン化合物に基づく骨再生材料 | |
| AU742748B2 (en) | Method of preparing a poorly crystalline calcium phosphate and methods of its use | |
| JPH0156777B2 (es) | ||
| US7150879B1 (en) | Neutral self-setting calcium phosphate paste | |
| EP0166263A1 (en) | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition | |
| JPH0233388B2 (es) | ||
| JPS63125259A (ja) | リン酸カルシウム系多孔質骨補填材 | |
| JP5865431B2 (ja) | リン酸カルシウムを含有する生体材料 | |
| Havlik et al. | Hydroxyapatite | |
| JPH10151188A (ja) | 骨形成用移植体 | |
| JPH08276003A (ja) | 硬組織修復材料および埋入型医療用具 | |
| JPH047227B2 (es) | ||
| JPH0414584B2 (es) | ||
| JP2003335574A (ja) | 貫通孔を有する球状リン酸カルシウム系セラミックス及びその用途 | |
| WO2003075973A1 (fr) | Moulage spherique de phosphate de calcium et son utilisation | |
| JPH0588623B2 (es) | ||
| JPS6366106A (ja) | 骨誘導生体材料 | |
| JP2555369B2 (ja) | 骨誘導生体材料 | |
| JPS63125258A (ja) | 骨欠損部、空隙部及び吸収部充てん材 | |
| JPH01107769A (ja) | 骨補填材 |